pharmacogenomics research Trinh Trung Duong Nguyen ,  Ziaurrehman Tanoli ,  Saad Hassan , Umut Onur Özcan ,   Jimmy Caroli ,   Albert J Kooistra ,   David E Gloriam ,   Alexander S Hauser GPCRdb in 2025: adding odorant search and models of physiological ligand complexes Luis P Taracena Herrera , Søren N Andreassen ,   Jimmy Caroli ,   Albert J Kooistra , Gáspár Pándy-Szekeres ,   David E Gloriam , et al.

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical Carola Weiss’ professional career brings deep expertise in business development, marketing & sales, licensing

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet Benjamin Franklin Medal in Chemistry from The Franklin Institute "Huge congratulations to our founder, Carol

This week's highlight includes congrats to: Miles Thompson , Alexander Hauser , Caroline Gorvin ,   et

December 2021 "Dame Carol Robinson DBE, FRS, FRSC, FMedSci, Oxford University’s first female Professor

Aylin Hanyaloglu, Caroline Gorvin, and Alejandra Tomas.

Miles Thompson, Alexander Hauser, Caroline Gorvin et al. for their research on GPCR gene variants and

This week's highlight includes congrats to: Miles Thompson ,   Alexander Hauser ,   Caroline Gorvin ,

Thompson , David Reiner-Link , Alessandro Berghella , Brinda K Rana , G Enrico Rovati , Valerie Capra , Caroline

pharmacology' Yao Lu and colleagues work on 'Molecular insights into orphan GPCRs relevant to schizophrenia' Carole

Industry News Professor Dame Carol Robinson Received 2023 ASMS John.B.Fenn Award Exscientia Announces

that utilizes state-of-the-art tools developed by Professor Terry Kenakin at the University of North Carolina

on GPCR Biased Signaling Terry Kenakin, Ph.D., Professor of Pharmacology at the University of North Carolina

identification of selective antagonists Industry News Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina